{"name":"Axxonis Pharma AG","slug":"axxonis-pharma-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Continuous Subcutaneous Lisuride Infusion","genericName":"Continuous Subcutaneous Lisuride Infusion","slug":"continuous-subcutaneous-lisuride-infusion","indication":"Parkinson's disease with motor fluctuations and dyskinesias","status":"phase_3"}]}],"pipeline":[{"name":"Continuous Subcutaneous Lisuride Infusion","genericName":"Continuous Subcutaneous Lisuride Infusion","slug":"continuous-subcutaneous-lisuride-infusion","phase":"phase_3","mechanism":"Lisuride is a dopamine agonist that activates dopamine receptors to improve motor symptoms and reduce involuntary movements in Parkinson's disease.","indications":["Parkinson's disease with motor fluctuations and dyskinesias"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPZkpDYXlpM1NuSnpIWWh3dzB1TWpKZk40NV9jMWdUdHhaM29KMUxkMUduOU1yS2lVV183ek5WVWpJVzlYLUpFUmtlS1ZkTW1FNXExX2ltQVR0NDZpY1g0LTk3SVlWT0RfQk1penV6Vkd2T3Z4OTZjYk1wYWdmWHBId2UxODF0dFhHUTBrekFZUnNSbS01SzhKTzVqb0FDLUVE?oc=5","date":"2021-03-02","type":"pipeline","source":"openPR.com","summary":"Restless Legs Syndrome Market is Booming with Market Strategies - openPR.com","headline":"Restless Legs Syndrome Market is Booming with Market Strategies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}